What is Complexa?
Complexa Inc. operates at the intersection of biotechnology and clinical medicine, specifically targeting the underlying mechanisms of fibrosis and inflammatory disorders. The company is dedicated to transforming patient outcomes through the development of novel therapeutic candidates designed to mitigate the progression of severe, life-threatening conditions. By focusing on high-unmet-need areas, Complexa has established itself as a critical player in the biopharmaceutical sector, bridging the gap between laboratory discovery and clinical application. Its market position is bolstered by a strategic focus on precision medicine and a commitment to rigorous clinical validation, which has attracted significant interest from institutional investors and venture capital firms alike.
How much funding has Complexa raised?
Complexa has raised a total of $90.1M across 10 funding rounds:
Private Equity
$2M
Series A
$3.6M
Debt
$1.4M
Private Equity
$200K
Series B
$14.8M
Debt
$4M
Debt
$950K
Debt
$1M
Series C
$62M
Debt
$150K
Private Equity (2012): $2M, investors not publicly disclosed
Series A (2012): $3.6M led by Pittsburgh Life Sciences Greenhouse
Debt (2013): $1.4M, investors not publicly disclosed
Private Equity (2013): $200K featuring Pittsburgh Life Sciences Greenhouse
Series B (2014): $14.8M backed by Pittsburgh Life Sciences Greenhouse
Debt (2015): $4M, investors not publicly disclosed
Debt (2016): $950K, investors not publicly disclosed
Debt (2016): $1M, investors not publicly disclosed
Series C (2017): $62M featuring New Enterprise Associates, HBM Healthcare Investments, Edmond de Rothschild Investment Partners, and JAFCO
Debt (2020): $150K backed by PPP
Key Investors in Complexa
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded investment company focused on the global healthcare sector, with a diversified portfolio of private and publicly listed companies.
Edmond de Rothschild Investment Partners
Edmond de Rothschild, founded in 1923 and headquartered in France, is an investment banking firm offering various financial services and solutions.
What's next for Complexa?
Looking ahead, the infusion of capital positions Complexa to accelerate its clinical development programs and potentially expand its therapeutic portfolio. The company is expected to prioritize the advancement of its lead candidates through late-stage trials, a phase that requires substantial financial runway and operational expertise. As the firm transitions into this next lifecycle stage, the focus will likely shift toward regulatory milestones and potential commercialization strategies. The continued support from its investor base provides the necessary stability to navigate the complexities of the biopharmaceutical regulatory environment, while also enabling the pursuit of strategic partnerships that could further validate its technology and broaden its market reach.
See full Complexa company page
